LICENSE AGREEMENT AMENDMENT
Exhibit 10.49
LICENSE AGREEMENT AMENDMENT
Inasmuch as NewLink Genetics Corporation of Ames, Iowa, and the Medical College of Georgia Research Institute of Augusta Georgia, have a valid and existing License Agreement related to the use of Indoleamine-2,3-Dioxygenase and its inhibitors in Immuno-regulation [*] dated September 13, 2005;
and
Inasmuch as the parties agree that the License Agreement contains a provision (Section 4.1) for the acquisition of new, related Improvement Technologies by NewLink arising at MCGRI after the Agreement was signed
and
Inasmuch as the NewLink has reviewed a new Improvement Technology [*], and wishes to exercise its option to incorporate this technology into the existing License Agreement technology portfolio under its standard royalty terms and use conditions,
It is Agreed:
That the parties amend the License Agreement relative to its Exhibit A , such that MCG case [*] is to be included in the technology portfolio for development and commercialization by NewLink, effective the date that the License Fee of [*] is received at MCGRI. All Payments due to the [*] will be coordinated by MCGRI according to the terms stated in [*].
This present amendment shall hereby be considered part of the original License Agreement and is hereto agreed by representatives of both parties signing below.
|
MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE |
|
|
NEWLINK GENETICS | ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By |
/s/Xxxxx Xxxxxxxx |
|
|
By: |
/s/Xxxxxxxx X. Xxxxxxxx |
|
Name: |
Xxxxx Xxxxxxxx |
|
Name: |
Xxxxxxxx X. Xxxxxxxx | |
|
Title: |
Executive Director |
|
Title: |
Chief Medical and Operations Officer | |
|
Date: |
2/13/07 |
|
|
Date: 2/6/07 | |
